TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Post radiosurgical AVM nidus obliteration on DSA
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Safety and tolerance of transplantation
Endpoint domain: Adverse events/effects
Primary endpoint: Feasibility of participant recruitment
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Feasibility of participant retention
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Acceptability of intervention among participants
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Adverse Events Leading to Dose Reduction of AZD2014
Endpoint domain: Adverse events/effects
Primary endpoint: AZD2014 Peak Plasma Concentration at Steady State (Cmax,ss)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence rate of dose-limiting toxicities (DLTs)
Endpoint domain: Adverse events/effects
Primary endpoint: Number of adverse events related to study treatment
Endpoint domain: Adverse events/effects
Primary endpoint: Number participants with dose interruptions and dose adjustments
Endpoint domain: Adverse events/effects
Primary endpoint: T cell subset T Helper 1
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: T cell subset T Helper 2
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: T cell subset Regulatory T Cell
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Interleukin-10
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Smash quality (Power)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Smash quality (Speed)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Smash quality (Distance)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Visual and quantitative analysis of lung CT scans
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Change in Depression, Anxiety, Stress
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Percentage of Meibum Quality Responders
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Procedure difficulties
Endpoint domain: Adverse events/effects
Primary endpoint: Procedure complications
Endpoint domain: Adverse events/effects
Primary endpoint: Self-reported number of cigarettes smoked
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Osteoradionecrosis status
Endpoint domain: Adverse events/effects
Primary endpoint: Mean number of concurrent medications
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Post-infusion survival
Endpoint domain: Mortality/survival
Primary endpoint: number of patients successfully extubated and/or transferred out of critical care
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: number of patients discharged from the hospital
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: increase in standardized uptake values (SUV)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in levels of 24 hour urinary free cortisol
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Primary union score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Structure, thickness, and presence of microbes of biofilm
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: myocardial oxygenation signal intensity changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Proportion of recommended medication
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Hamilton Depression Rating Scale (Ham-D)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: sensitivity and specificity of algorithms in predicting HIV infection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Body Weight After Intervention
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in lung ultrasound score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Relative change in bone mineral density (BMD) of the lumbar spine
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Pathological Complete Response (pCR) rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Improvement in symptoms of gastroparesis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Child Dental Anxiety
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Referral to Child Protective Services for neglect
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Adherence to recommended medical care
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Baseline urinary NGF level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Capillary blood lactate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Subjective Overall Comfort Rating
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change From Baseline in Ocular Surface Disease Index© Questionnaire Score
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Proportion of patients with a complete response (CR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Maximal degree of tumor regression
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Number of ABI Complications
Endpoint domain: Adverse events/effects
Primary endpoint: Change in Gout Pain Intensity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to First New Flare
Endpoint domain: Mortality/survival
Primary endpoint: Accuracy of Freestyle Libre flash monitoring
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Baseline level and change in rate of oxygen consumption
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Baseline level and change in rate of carbon dioxide production
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Baseline level and change in respiratory exchange ratio (RER)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Baseline level and change in urinary nitrogen excretion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change from baseline in body weight
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change of Sitting Systolic Blood Pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Time taken between administration of 1st dose of drugs and delivery
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean Monthly Migraine Days
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change From Unified Parkinson's Disease Rating Scale - UPDRS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Complication rate following Mohs micrographic surgery and flap inset
Endpoint domain: Adverse events/effects
Primary endpoint: Complication rate following flap takedown
Endpoint domain: Adverse events/effects
Primary endpoint: Frequency of incisional hernia
Endpoint domain: Adverse events/effects
Primary endpoint: Operative Duration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Gingival Laceration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Operative Pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Analgesics Intake
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: C-reactive Protein
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Tolerability of Test Products
Endpoint domain: Adverse events/effects
Primary endpoint: Overall response rate (complete response and partial response)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of Recurrent Symptomatic Hemorrhage
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: 3-year Progression-free Survival Rate
Endpoint domain: Mortality/survival
Primary endpoint: Observed maximum plasma concentration (Cmax)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Terminal half life (t1/2)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of ventilator associated pneumonia
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Subjects Aged 18-49 Years Reporting Solicited Local Adverse Events (AEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Subjects Aged 18-49 Years Reporting Any, Grade 3 and Related Solicited General Symptoms
Endpoint domain: Adverse events/effects
Primary endpoint: Humoral Immune Response in Terms of Haemagglutination Inhibition (HI) Antibodies in Subjects Aged 3-17 Years by Calculating Serum Antihaemagglutination (HA) Antibody Titers Against the 4 Vaccine Strains
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Superiority of Limberg Flap
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Increase in Motor Evoked Potential (MEP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Increase in amplitude in the gamma frequency band (24-60 Hz) of resting qEEG
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Time to First Peak Ground Reaction Force in the Sagittal Plane (T1)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Second Peak Ground Reaction Force in the Sagittal Plane (F2)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: IL-13 production levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Percentage Change in Acne Lesion Swelling (Height)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Mobilisation of adipose tissue
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Degree of correction at initial brace wear
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in 10 Meter Walk Test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Action Research Arm Test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prevalence of a History of Cardiovascular Disease
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Presence and width of trilaminar endometrium
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Overactive symptom score (OABSS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum plasma concentration (Cmax) of selatogrel
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the plasma concentration-time curve (AUC0-inf) of selatogrel
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Efficacy assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time of neutrophils reconstruction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Number of participants with adverse events (AE) or severe adverse events (SAE)
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Patients With Serious Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Patients With Adverse Events Leading to Discontinuation
Endpoint domain: Adverse events/effects
Primary endpoint: Difference in VAS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Uterine tone
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Graft rejection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Brain Tumor Responses to Therapy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Best Corrected Visual Acuity (BSCVA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Intraoperative perforation rate
Endpoint domain: Adverse events/effects
Primary endpoint: Changes in HbA1C from baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Transient Acute Kidney Injury
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Persistent Acute Kidney Injury
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Plasma concentration of Paliperidone (Period 1)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Plasma concentration of Paliperidone (Period 2)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from Baseline Emotion Regulation Task at End of Treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from Baseline Emotional Go/No-Go Task at End of Treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Simple Shoulder Test
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Incidence of Acute GVHD (Grades III-IV)
Endpoint domain: Adverse events/effects
Primary endpoint: TOX Rate
Endpoint domain: Adverse events/effects
Primary endpoint: Time to first occurrence of composite primary outcome event
Endpoint domain: Mortality/survival
Primary endpoint: Persistent eGFR decline of greater than or equal to 50%
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Reaching ESRD
Endpoint domain: Mortality/survival
Primary endpoint: Complete Remission (CR)
Endpoint domain: Mortality/survival
Primary endpoint: Symptom relief
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Dizziness handicap Inventory
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Nerve signal detection time
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Prevalence of C-shaped root canal
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence rate of no delayed nausea and vomiting
Endpoint domain: Adverse events/effects
Primary endpoint: Kt-1000 Stability
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Isokinetic Knee tests
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Response rate of overall symptom improvement
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: reactivity of juvenile platelets
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Change in Irritable bowel syndrome severity scoring system (IBS-SSS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Assessment of response rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to negative conversion of SARS-CoV-2 nasopharyngeal swab
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Psychoactive effects of GH001
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prealbumin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Free Triiodothyronine (FT3)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Parathormone (PTH)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Sensitivity and specificity in screening cancer patients
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Goldmann visual field area changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Blood clot firmness
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Percentage of Participants With a ≥ 50% Decrease in Sperm Concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Percentage of Subjects With Anti-measles Virus Antibody Concentration Equal to or Above the Cut-off-value
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Percentage of Subjects With Anti-mumps Virus Antibody Concentration Equal to or Above the Cut-off-value
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Percentage of Subjects With Anti-rubella Virus Antibody Concentration Equal to or Above the Cut-off-value
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change in nasal potential difference (NPD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum Tolerated Dose (MTD) of PX-12
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Blunting of NLRP3 inflammasome
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: skin wrinkle
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Side effects of drugs
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants With Grade 2 or 3 Urgency Episodes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Absence of Anterior Chamber Cells at Day 15
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ocular outcomes
Primary endpoint: Absence of Ocular Pain at Day 4
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ocular outcomes
Primary endpoint: Area under plasma concentration-time curve (AUC) at steady state
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With Ocular and Non-Ocular Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Change of intima media thickness of the common carotid artery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Presence of asthma phenotype
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Asthma severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Serum IL-16 concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Pain assessment with Algometry
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pain assessment with The Leeds Assessment of Neuropathic Symptoms and Signs (LANSS) pain scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pain assessment with Visual Analog Scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: IIEF Erectile Function (EF) Domain score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prevalence of severe asthma
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Attentional Bias to Marijuana Specific Stimuli
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Stress as Assessed by the Perceived Stress Scale
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Anxiety as Assessed by the Zung Self-Rated Anxiety Scale
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Electrophysiological properties
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Remodeling in right atrium
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: 2-Year Treatment Discontinuation Rate
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Clinical efficacy of DP
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: stroke recurrence rate
Endpoint domain: Mortality/survival
Primary endpoint: Change in tonic electrical activity of the diaphragm (EAdi)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Stability index
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: The near point of convergence (NPOC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: The CROM
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Blood Phenylalanine Concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change of body fat mass
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change of Triglyceride
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change of Total cholesterol
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Percentage of impaired scaled score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes